Litcius/Paper detail

Fenretinide regulates macrophage polarization to protect against experimental colitis induced by dextran sulfate sodium

Yong Cao, Yan Lin, Yan Sun, Weiyu Liu, Yichuan Shao, Changqing Zheng

2020Bioengineered15 citationsDOIOpen Access PDF

Abstract

Fenretinide (4-HPR), a synthetic retinoid, has attracted attention for its anti-inflammation activity. However, few studies have evaluated the effects of 4-HPR on ulcerative colitis (UC). The present study was performed to investigate the therapeutic effects of 4-HPR on UC, and to explore the mechanisms mainly focused on macrophage polarization involved in this progress. Intraperitoneally administered 4-HPR particularly at dose of 100 mg/kg obviously alleviated UC symptoms and restrained the mRNA expression of colonic IL-1β, IL-6, and TNF-α in dextran sulfate sodium (DSS)-induced mice. Further analysis showed that 4-HPR decreased the mRNA expression of M1 macrophage markers IL-12 and iNOS, while increased M2 macrophage markers Ym1, Arg1 and MRC1 in colonic tissue of mice received DSS. Consistently, an in vitro study revealed that 4-HPR decreased inflammatory response and M1 polarization, while enhanced M2 polarization in LPS-induced RAW264.7 cells. Interestingly, 4-HPR remarkably activated PPAR-γ which was an important regulator of macrophage polarization both in colonic tissue of UC mice and in LPS-induced RAW264.7 cells. Furthermore, these effects of 4-HPR in vivo and in vitro including anti-inflammation and modulation of macrophage polarization were partially abolished by treatment with PPAR-γ antagonist GW9662, indicating that 4-HPR activated PPAR-γ to exert its activities. Taken together, this study demonstrated that 4-HPR might be a potent anti-UC agent that works by regulating macrophage polarization via PPARγ.

Topics & Concepts

Macrophage polarizationM2 MacrophageColitisIn vivoChemistryInflammationMacrophageIn vitroPharmacologyFenretinideInternal medicineImmunologyRetinoidMedicineBiologyRetinoic acidBiochemistryGeneBiotechnologyImmune cells in cancerInflammatory Bowel DiseaseImmune Response and Inflammation